Study of Mometasone Furoate/Formoterol Combination and Fluticasone/Salmeterol in Persistent Asthmatics Previously Treated With Inhaled Glucocorticosteroids (P04139)

NCT ID: NCT00379288

Last Updated: 2024-05-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 404 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-06-30
• Study Completion Date: 2007-11-30

Brief Summary

The purpose of this study is to evaluate the long-term safety of mometasone furoate/formoterol (MF/F) metered dose inhaler (MDI) 200/10 mcg twice-a-day (BID) and MF/F MDI 400/10 mcg BID and two doses of fluticasone/salmeterol combination (F/SC) (250/50 mcg BID and 500/50 mcg BID) in subjects with persistent asthma who require maintenance treatment on inhaled glucocorticosteroids (ICS); evaluator-blind.

In addition, the extrapulmonary effects on 24-hour plasma cortisol area under curve (AUC), of MF/F MDI 200/10 mcg BID, MF/F MDI 400/10 mcg BID, F/SC MDI 250/50 mcg BID, and F/SC MDI 500/50 mcg BID will be evaluated.

Conditions

Asthma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

MF/F 200/10 mcg BID

Group Type: EXPERIMENTAL

mometasone furoate combination MDI 200/10 mcg BID

Intervention Type: DRUG

MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 1 year

MF/F 400/10 mcg BID

Group Type: EXPERIMENTAL

mometasone furoate combination MDI 400/10 mcg BID

Intervention Type: DRUG

MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 1 year

F/SC 250/50 mcg BID

Group Type: ACTIVE_COMPARATOR

Fluticasone/Salmeterol 250/50 mcg BID

Intervention Type: DRUG

F/SC 250/50 twice daily for 1 year

F/SC 500/50 mcg BID

Group Type: ACTIVE_COMPARATOR

Fluticasone/Salmeterol 500/50 mcg BID

Intervention Type: DRUG

F/SC 500/50 twice daily for 1 year

Interventions

mometasone furoate combination MDI 200/10 mcg BID

MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 1 year

Intervention Type: DRUG

mometasone furoate combination MDI 400/10 mcg BID

MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 1 year

Intervention Type: DRUG

Fluticasone/Salmeterol 250/50 mcg BID

F/SC 250/50 twice daily for 1 year

Intervention Type: DRUG

Fluticasone/Salmeterol 500/50 mcg BID

F/SC 500/50 twice daily for 1 year

Intervention Type: DRUG

Other Intervention Names

SCH 418131; SCH 418131; Seretide; Seretide

Eligibility Criteria

Inclusion Criteria

• Subjects of either sex and any race, at least 12 years of age, with a diagnosis of asthma of at least 12 months.
• Use of medium or high daily dose of ICS (alone or in combination with long-acting beta-agonist [LABA]) for at least 12 weeks prior to Screening and have been on a stable regimen for at least 2 weeks prior to Screening.

• Medium daily doses of ICS:

• > 500 to 1000 mcg beclomethasone chlorofluorocarbon (CFC)
• > 250 to 500 mcg beclomethasone hydrofluoroalkane (HFA)
• > 600 to 1000 mcg budesonide dry powder inhaler (DPI)
• > 1000 to 2000 mcg flunisolide
• > 250 to 500 mcg fluticasone
• 400 mcg MF
• > 1000 to 2000 mcg triamcinolone acetonide
• High daily doses of ICS:

• > 1000 mcg beclomethasone CFC
• > 500 mcg beclomethasone HFA
• > 1000 mcg budesonide DPI
• > 2000 mcg flunisolide
• > 500 mcg fluticasone
• > 400 mcg MF
• > 2000 mcg triamcinolone acetonide
• If there is no inherent harm in changing the subject's current asthma therapy, the subject must discontinue prescribed ICS or ICS/LABA combination at Baseline.
• Must show evidence of reversibility within the last 12 months or during the Screening Period. Historical reversibility defined as an increase in absolute forced expiratory volume in 1 second (FEV1) of >= 12% and >= 200 mL will qualify if performed within 12 months of Screening. If no historical reversibility, subject must demonstrate an absolute FEV1 of >= 12% and >= 200 mL within 10 to 15 minutes after four puffs of salbutamol at Visit 1 or anytime prior to Baseline.
• At Screening and Baseline, FEV1 must be >= 50% predicted, when restricted medications are withheld for the appropriate intervals.
• Complete blood count, blood chemistries, urinalysis, and electrocardiogram (ECG) conducted at Screening must be within normal limits or clinically acceptable to the investigator/sponsor. A chest x-ray performed at Screening or within 12 months prior must be clinically acceptable.
• A female of childbearing potential must be using a medically acceptable, adequate form of birth control:

• prescribed hormonal contraceptives;
• medically prescribed intrauterine device (IUD);
• medically prescribed transdermal contraceptive;
• condom in combination with spermicide;
• monogamous relationship with a male partner who has had a vasectomy.

Birth control must have started at least 3 months prior to Screening. Subject must agree to continue its use for the duration of the study. A subject of childbearing potential who is not currently sexually active must agree to use a medically acceptable method should she become sexually active during the study. Women who have been surgically sterilized or are at least 1 year postmenopausal are not considered to be of childbearing potential. A subject of childbearing potential must have a negative serum pregnancy test at Screening.

Exclusion Criteria

• A change (increase or decrease) in absolute FEV1 of > 20% at any time from the Screening Visit up to, and including, the Baseline Visit.
• A subject who requires the use of > 12 inhalations per day of short-acting beta-agonist (SABA) MDI or > 2 nebulized treatments per day of 2.5 mg salbutamol, on any 2 consecutive days from the Screening Visit up to, and including, the Baseline Visit.
• A subject who experiences a clinical asthma exacerbation (defined as a deterioration of asthma that results in emergency treatment, hospitalization due to asthma, or treatment with additional, excluded asthma medication [other than SABA]) at any time from the Screening Visit up to, and including, the Baseline Visit.
• A subject who has ever required ventilator support for respiratory failure secondary to asthma.
• A subject who is a smoker or ex-smoker and has smoked within the previous year or has had a cumulative smoking history > 10 pack-years.

• Minimum Eligible Age: 12 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Organon and Co

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

References

Maspero JF, Nolte H, Cherrez-Ojeda I; P04139 Study Group. Long-term safety of mometasone furoate/formoterol combination for treatment of patients with persistent asthma. J Asthma. 2010 Dec;47(10):1106-15. doi: 10.3109/02770903.2010.514634. Epub 2010 Nov 1.

Reference Type: RESULT

PMID: 20874458 (View on PubMed)

Oba Y, Anwer S, Maduke T, Patel T, Dias S. Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying doses of inhaled corticosteroids in adolescents and adults with asthma: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2022 Dec 6;12(12):CD013799. doi: 10.1002/14651858.CD013799.pub2.

Reference Type: DERIVED

PMID: 36472162 (View on PubMed)

Maspero J, Cherrez I, Doherty DE, Tashkin DP, Kuna P, Kuo WL, Gates D, Nolte H, Chylack LT Jr. Appraisal of lens opacity with mometasone furoate/formoterol fumarate combination in patients with COPD or asthma. Respir Med. 2014 Sep;108(9):1355-62. doi: 10.1016/j.rmed.2014.04.015. Epub 2014 May 2.

Reference Type: DERIVED

PMID: 25044280 (View on PubMed)

Other Identifiers

P04139

Identifier Type: -

Identifier Source: org_study_id